AnalystsChad MesserChad Messer's Stock Forecasts
AnalystsChad Messer
Sectors:
Analyst Ranking
Bottom 2%
#5122 out of 5185 analysts
Average Return
-11.71%
Win Rate
30%13 out of 43
Risk vs Reward
Poor
Good
Chad Messer's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Immunome IncIMNM | +266.92% | $6.71 | $24.62 | 2025-04-02 - 2026-01-30 | Strong Buy |
G1 Therapeutics IncGTHX | +129.24% | $17.99 | $41.24 | 2017-06-12 - 2018-06-12 | Buy |
Arqule IncARQL | +116.11% | $1.49 | $3.22 | 2017-12-14 - 2018-12-14 | Buy |
Juno Therapeutics IncJUNO | +81.17% | $48.00 | $86.96 | 2018-01-05 - 2018-03-05 | Buy |
Athersys IncATHXQ | +45.69% | $29.00 | $42.25 | 2017-02-07 - 2018-02-07 | Buy |
Chad Messer Analyst Color
Get additional color on Chad Messer's coverage of popular stocks
Chad Messer's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Immunome IncIMNM | 2 | Strong Buy | $32.00 | +29.98% | Maintains | 2 months ago |
Os Therapies IncOSTX | 2 | Strong Buy | $17.00 | +1,150.00% | Maintains | 2 months ago |
Genelux CorpGNLX | 1 | Strong Buy | $16.00 | +501.50% | Initiates Coverage On | 3 months ago |
Monopar TherapeuticsMNPR | 1 | Strong Buy | $106.00 | +75.55% | Initiates Coverage On | 4 months ago |
Oncolytics Biotech IncONCY | 1 | Strong Buy | $7.00 | +613.56% | Initiates Coverage On | 6 months ago |
Coya Therapeutics IncCOYA | 1 | Strong Buy | $16.00 | +244.09% | Initiates Coverage On | 7 months ago |
Bolt Biotherapeutics IncBOLT | 1 | Strong Buy | $80.00 | +1,255.93% | Initiates Coverage On | 8 months ago |
Lantern Pharma IncLTRN | 1 | Strong Buy | $25.00 | +693.65% | Initiates Coverage On | 10 months ago |
Esperion Therapeutics IncESPR | 2 | Strong Buy | $114.00 | N/A | Maintains | 4 years ago |
Celcuity IncCELC | 1 | Buy | $50.00 | N/A | Initiates Coverage On | 5 years ago |
Cytokinetics IncCYTK | 2 | Buy | $48.00 | N/A | Maintains | 5 years ago |
Exelixis IncEXEL | 3 | Buy | $30.00 | N/A | Maintains | 5 years ago |
Phasebio Pharmaceuticals IncPHASQ | 2 | Buy | $15.00 | N/A | Maintains | 5 years ago |
Avidity Biosciences IncRNA | 1 | Buy | $50.00 | N/A | Initiates Coverage On | 5 years ago |
Cormedix IncCRMD | 2 | Buy | $29.00 | N/A | Maintains | 5 years ago |
Mereo Biopharma Group PLCMREO | 1 | Buy | $10.00 | N/A | Initiates Coverage On | 5 years ago |
Ionis Pharmaceuticals IncIONS | 2 | Buy | $86.00 | N/A | Maintains | 5 years ago |
Novabridge BiosciencesNBP | 1 | Buy | $75.00 | N/A | Initiates Coverage On | 5 years ago |
Gamida Cell LtdGMDAQ | 1 | Buy | $14.00 | N/A | Maintains | 5 years ago |
G1 Therapeutics IncGTHX | 2 | Buy | $68.00 | N/A | Maintains | 5 years ago |
Genocea Biosciences IncGNCAQ | 1 | Buy | $6.00 | N/A | Maintains | 5 years ago |
Sarepta Therapeutics IncSRPT | 1 | Buy | $166.00 | N/A | Maintains | 5 years ago |
Nurix Therapeutics IncNRIX | 1 | Buy | $35.00 | N/A | Initiates Coverage On | 5 years ago |
Seagen IncSGEN | 3 | Buy | $188.00 | N/A | Maintains | 6 years ago |
Athersys IncATHXQ | 2 | Buy | $125.00 | N/A | Maintains | 6 years ago |
Spyre Therapeutics IncSYRE | 1 | Buy | $275.00 | N/A | Maintains | 6 years ago |
Akebia Therapeutics IncAKBA | 1 | Buy | $18.00 | N/A | Maintains | 6 years ago |
Akcea Therapeutics IncAKCA | 1 | Buy | $45.00 | N/A | Initiates Coverage On | 7 years ago |
Juno Therapeutics IncJUNO | 1 | Buy | $65.00 | N/A | Initiates Coverage On | 8 years ago |
Arqule IncARQL | 1 | Buy | N/A | N/A | Upgrades | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.